Evaluation of an animal model system for cryptosporidiosis: therapeutic efficacy of paromomycin and hyperimmune bovine colostrum-immunoglobulin
about
Mediation of Cryptosporidium parvum infection in vitro by mucin-like glycoproteins defined by a neutralizing monoclonal antibody.Paromomycin and geneticin inhibit intracellular Cryptosporidium parvum without trafficking through the host cell cytoplasm: implications for drug delivery.Efficacy of nitazoxanide against Cryptosporidium parvum in cell culture and in animal modelsThe gamma interferon gene knockout mouse: a highly sensitive model for evaluation of therapeutic agents against Cryptosporidium parvumSynergistic anticryptosporidial potential of the combination alpha-1-antitrypsin and paromomycinAnnotated draft genome sequences of three species of Cryptosporidium: Cryptosporidium meleagridis isolate UKMEL1, C. baileyi isolate TAMU-09Q1 and C. hominis isolates TU502_2012 and UKH1.Sequence polymorphism in the beta-tubulin gene reveals heterogeneous and variable population structures in Cryptosporidium parvumTransmission and serial propagation of Enterocytozoon bieneusi from humans and Rhesus macaques in gnotobiotic pigletsGenomics and population biology of Cryptosporidium species.Recombinant proteins of Cryptosporidium parvum induce proliferation of mesenteric lymph node cells in infected miceIntestinal lesions associated with disseminated candidiasis in an experimental animal model.beta-tubulin mRNA as a marker of Cryptosporidium parvum oocyst viability.Characterization and formulation of multiple epitope-specific neutralizing monoclonal antibodies for passive immunization against cryptosporidiosis.Efficacy of monoclonal antibodies against defined antigens for passive immunotherapy of chronic gastrointestinal cryptosporidiosis.Detection and genotyping of oocysts of Cryptosporidium parvum by real-time PCR and melting curve analysis.Cryptosporidium parvum infection of Caco-2 cell monolayers induces an apical monolayer defect, selectively increases transmonolayer permeability, and causes epithelial cell death.A pig model of the human gastrointestinal tract.Characterization of Cryptosporidium meleagridis of human origin passaged through different host species.Evaluation of high-dose regimen of paromomycin against cryptosporidiosis in the dexamethasone-treated rat model.A new restriction fragment length polymorphism from Cryptosporidium parvum identifies genetically heterogeneous parasite populations and genotypic changes following transmission from bovine to human hosts.Antimicrobial therapy for the treatment of opportunistic infections in HIV/AIDS patients: a critical appraisal.Profiles of healing and nonhealing Cryptosporidium parvum infection in C57BL/6 mice with functional B and T lymphocytes: the extent of gamma interferon modulation determines the outcome of infection.Structure of Cryptosporidium IMP dehydrogenase bound to an inhibitor with in vivo antiparasitic activity.Rapid displacement of Cryptosporidium parvum type 1 by type 2 in mixed infections in piglets.Infection with Cryptosporidium hominis provides incomplete protection of the host against Cryptosporidium parvum.Cryptosporidium parvum, a potential cause of colic adenocarcinoma.Glycoproteins and Gal-GalNAc cause Cryptosporidium to switch from an invasive sporozoite to a replicative trophozoiteParasites and immunotherapy: with or against?Validation of IMP dehydrogenase inhibitors in a mouse model of cryptosporidiosis.Extensive polymorphism in Cryptosporidium parvum identified by multilocus microsatellite analysis.Molecular cloning and expression of a gene encoding Cryptosporidium parvum glycoproteins gp40 and gp15.Cryptosporidium parvum infection of human intestinal xenografts in SCID mice induces production of human tumor necrosis factor alpha and interleukin-8Genetic analysis of a Cryptosporidium parvum human genotype 1 isolate passaged through different host species.Identification of genetic heterogeneity in the Cryptosporidium parvum ribosomal repeat.The therapeutic efficacy of azithromycin and nitazoxanide in the acute pig model of Cryptosporidium hominisTranscriptome analysis of pig intestinal cell monolayers infected with Cryptosporidium parvum asexual stages.Therapeutic Efficacy of Bumped Kinase Inhibitor 1369 in the Acute Pig Model of Cryptosporidium hominis.
P2860
Q24515033-888CD10B-DF4E-46AC-A45B-868434268AB4Q28368293-F8E9F240-2194-4F44-B2FA-711C139F1B16Q28368312-6534AEC3-E54B-4132-93F2-2BF91E1E2AE5Q28368386-4DA5084A-E0F1-4644-8DBB-717932370855Q28379124-B0A833C1-39D8-4CFA-9458-90D197698165Q33609094-F9D1B470-B4B3-4C28-A042-F804DDBA6615Q33719152-1DBBC260-3D6E-4B3A-84A7-B439950AD337Q33768010-C142280B-1767-4661-B7CE-A3DBF6985C81Q33905799-69EE9B5C-5960-49DB-9080-8A18DA7707ACQ33946632-3D14D283-457A-49A9-BF55-48B309B874E7Q33967498-07FC1331-38B2-4599-9221-0674E8BCB174Q33984651-B9582FDF-18B5-4828-B50D-E7B87DE90ECEQ34004213-A6C4EBE2-7F7B-4154-A364-44B94D922FEFQ34105139-5AC089E6-C8A1-4D6D-8BA2-321ADEACA6C3Q34196302-9566B627-D2C0-425B-B9D8-E187EB45B8E5Q34541501-1417E757-5219-444E-BA0B-292AF376D287Q34645922-2AA19BA0-8966-4D61-B7AE-B60E2E5267CFQ34855383-0829A2D0-3F25-45FB-9A51-4DD7BFEEA6A0Q35118894-91B834D0-B592-4B02-BD8C-B81BB41AF1E5Q35556083-70F9C271-D529-4D2A-B72B-F417E053D58FQ35557331-C4E199E0-1A25-48FE-A8B8-47ACFAF436F9Q35558743-335FE690-7CB5-4130-8105-F68A4E37C0B0Q35592527-8F549FFC-E9C5-4119-B148-C6DB51636676Q36046487-7F5C3C91-60C0-4AB0-89C2-F88073FD3BA2Q36154220-517DFCE6-2F84-458C-9EFD-EA5CB1279D9BQ36412661-0C1BC3E4-F4A3-4877-AEC6-441C6AEB15E2Q36447701-C5C92E79-81B2-430A-973B-99AA1E8B6ACAQ37053248-BF54DF32-5175-4D7E-987E-849B31135317Q37643702-FB011493-E7DC-46F6-BC8F-ECE6D0BFC87DQ39486549-2210F6F9-A927-4384-A8D3-2A8D61258226Q39537744-5D0597F0-7A65-49C2-AE2C-498A806C9B4CQ39571349-09D85A8E-C59F-49F9-8439-2269057EE00EQ39656654-FF6E3812-8BFE-45EB-9E87-650FFB1A1A07Q39799335-F9699FF2-D91F-4AFA-8FE9-B0BE5205D0BAQ41991627-00950B88-EFB2-44EB-9949-83BD113C76E3Q52660152-A40A2486-B984-4CC9-8557-111B6BC27690Q54115803-835EC8C5-9BA0-4D57-804F-CC2410816534
P2860
Evaluation of an animal model system for cryptosporidiosis: therapeutic efficacy of paromomycin and hyperimmune bovine colostrum-immunoglobulin
description
1994 nî lūn-bûn
@nan
1994年の論文
@ja
1994年論文
@yue
1994年論文
@zh-hant
1994年論文
@zh-hk
1994年論文
@zh-mo
1994年論文
@zh-tw
1994年论文
@wuu
1994年论文
@zh
1994年论文
@zh-cn
name
Evaluation of an animal model ...... ovine colostrum-immunoglobulin
@en
type
label
Evaluation of an animal model ...... ovine colostrum-immunoglobulin
@en
prefLabel
Evaluation of an animal model ...... ovine colostrum-immunoglobulin
@en
P2093
P2860
P1476
Evaluation of an animal model ...... ovine colostrum-immunoglobulin
@en
P2093
P2860
P304
P577
1994-07-01T00:00:00Z